top menu action banner

REGONIX (REGORAFENIB) 40MG TABLETS 28`S

Ksh 27,999

In Stock

  • Product Categories:

WHAT IS THIS MEDICINE AND WHAT IS IT USED FOR?

Regonix contains regorafenib, a targeted cancer medicine that blocks a large number of proteins (receptor tyrosine kinases) involved in tumour blood vessel formation, tumour growth, and the tumour's local environment.

By attacking these multiple targets simultaneously, regorafenib inhibits tumour growth and cuts off the blood supply tumours need to survive.

It is used in adults for: metastatic colorectal cancer (bowel cancer that has spread) — after failure of standard chemotherapy and targeted therapies; gastrointestinal stromal tumours (GIST) — a type of bowel tumour — that have progressed on imatinib and sunitinib; and hepatocellular carcinoma (liver cancer) — as second-line treatment after sorafenib.

 

3. HOW TO TAKE THIS MEDICINE

The standard dose is 160mg (four 40mg tablets) once daily for the first 21 days of each 28-day cycle — 3 weeks on, then 1 week off. Take all four tablets together, once daily, with a low-fat breakfast (less than 30% fat content — such as toast with jam, or cereal with skimmed milk). Do not take on an empty stomach or with a high-fat meal — food affects absorption significantly. Swallow tablets whole — do not crush or chew. Take at the same time each day.

 

Regorafenib must be taken with a low-fat breakfast — not fasting, but specifically with a low-fat meal. A high-fat meal increases exposure by up to 50%, while fasting reduces it. The low-fat breakfast requirement is not optional. A typical suitable breakfast: two slices of white toast with jam and a glass of juice — avoiding butter, eggs, cheese, or fried foods.

 

PATIENT TIP: Hand-foot skin reaction (palmar-plantar erythrodysaesthesia) is one of the most common and potentially debilitating side effects — redness, tenderness, thickening, and blistering of the palms and soles. Start preventative measures from day 1: moisturise palms and soles with a thick cream (urea-based preferred) twice daily before any symptoms appear. Wear well-cushioned, comfortable footwear. Avoid activities that create friction or pressure on the hands and feet.

 

4. POSSIBLE SIDE EFFECTS

How Common?

Side Effects

Very Common

Hand-foot skin reaction (palmar-plantar erythrodysaesthesia — redness, blistering, pain of palms and soles), fatigue, diarrhoea, reduced appetite, high blood pressure (hypertension), raised liver enzymes, nausea, hoarseness of voice, pain, weight loss, infection

Common

Mucositis (mouth sores), skin rash, hair colour changes, hypothyroidism (underactive thyroid), raised lipase (risk of pancreatitis), fever, thrombocytopenia

Serious — Tell Your Doctor Promptly

Severe liver toxicity (hepatotoxicity): jaundice, dark urine, severe right upper abdominal pain — can be fatal; requires urgent LFT review and possible drug discontinuation. Gastrointestinal perforation or fistula: sudden severe abdominal pain — medical emergency. Severe hypertensive crisis: seek emergency care. Serious bleeding events. Skin infections complicating hand-foot reaction (cellulitis). Posterior reversible encephalopathy syndrome (PRES): headache, visual disturbance, seizures, confusion — rare but serious.

 

5. WHO SHOULD NOT TAKE THIS MEDICINE

Regorafenib must not be used during pregnancy — highly teratogenic. Effective contraception is essential during treatment and for at least 2 months after the last dose. It should not be used in patients with severe liver impairment (Child-Pugh C). Use with great caution in patients with high blood pressure, a history of bleeding, or recent major surgery.

 

LIVER TOXICITY IS THE PRIMARY SAFETY CONCERN: Regorafenib causes significant liver toxicity in a proportion of patients — including fatal cases. LFT monitoring is essential before each cycle. Report jaundice, dark urine, or severe abdominal pain to your oncologist immediately — do not wait until your next appointment.

BLOOD PRESSURE MUST BE MONITORED DAILY: Hypertension develops in many patients. Monitor blood pressure at home every day and keep a log. Contact your oncology team if BP consistently exceeds 150/100 mmHg — antihypertensive treatment will likely be needed.

HAND-FOOT SKIN REACTION — START PREVENTION EARLY: Begin thick moisturising cream on palms and soles from day 1 of treatment, before any symptoms appear. Protective insoles and soft footwear from the start. Report Grade 2 or 3 reactions (blistering, inability to walk or use hands) to your oncologist — dose reduction may be required.

 

6. MEDICINES THAT INTERACT WITH THIS TREATMENT

Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice) significantly increase regorafenib exposure — avoid.

Strong CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, St. John's Wort) significantly reduce regorafenib levels — avoid. Regorafenib inhibits UGT1A1 (an enzyme that processes bilirubin and some drugs) — it can raise bilirubin levels and interfere with metabolism of drugs such as irinotecan and rosuvastatin.

Warfarin: closely monitor INR — regorafenib can affect warfarin metabolism.

 

7. HOW TO STORE THIS MEDICINE

Store below 30°C. Keep in original blister pack. Do not store in damp places (e.g. bathroom cabinet). Use within 7 weeks of opening the blister. Keep out of reach of children.

 

8. PRESCRIPTION REQUIREMENT

Field

Details

Status

Prescription Only Medicine (POM) — Specialist (oncology) prescription required

 

9. GUIDANCE FOR PATIENTS & CAREGIVERS

Take four 40mg tablets once daily with a low-fat breakfast — not fasting, and not with a high-fat or fried meal. Stick to simple, low-fat foods (toast, cereal, fruit) with each daily dose. Monitor your blood pressure every day and keep a log.

Start thick moisturiser on your palms and soles from day 1 — before any skin symptoms appear. Attend all liver blood test appointments without fail. Report yellow skin or eyes, dark urine, or severe tummy pain immediately. Avoid grapefruit and grapefruit juice. Use effective contraception throughout treatment and for 2 months after your last dose.

 

10. PHARMACIST & PRESCRIBER NOTES

Field

Details

Clinical Dispensing Notes

Low-fat breakfast administration is mandatory — not fasting, not high-fat. Specifically low-fat (<30% fat content). LFT monitoring: before each cycle and as clinically indicated — hepatotoxicity can be fatal; Grade 3+ ALT/AST requires dose interruption. BP monitoring: daily home monitoring; antihypertensive treatment initiated promptly if BP >150/100 mmHg. Hand-foot skin reaction (HFSR) prevention: proactive counselling from day 1 — urea-based emollient to palms and soles, pressure-relieving footwear. Grade 2 HFSR requires dose interruption; Grade 3 requires dose reduction. CYP3A4 inhibitor/inducer screening — grapefruit avoidance. UGT1A1 inhibitor: bilirubin elevation expected (may be pharmacological, not hepatotoxic — interpret in context of ALT/AST). Warfarin INR monitoring. 3-weeks-on, 1-week-off cycle — counsel clearly. Blister: use within 7 weeks of opening. Embryo-fetal toxicity: contraception during and 2 months post-treatment.

 

11. FREQUENTLY ASKED QUESTIONS

Q: What is hand-foot skin reaction and how do I prevent it?

Hand-foot skin reaction (also called palmar-plantar erythrodysaesthesia) is a common side effect where the palms and soles become red, sore, tender, thickened, or blistered. The key is prevention: start applying a thick, urea-based moisturiser to your palms and soles twice daily from day 1 — before any symptoms appear. Wear well-cushioned, comfortable footwear with soft insoles and avoid activities that create friction or pressure on your hands and feet.

Q: Why are liver blood tests so important?

Regorafenib can cause significant and occasionally fatal liver toxicity. Regular liver function tests before each cycle allow your oncologist to detect problems early and adjust your dose if needed. Never skip these blood tests, and report any yellow colouring of your skin or eyes, dark urine, or persistent severe upper tummy pain immediately.

Q: How often do I take the medicine?

Regorafenib is taken in cycles of 3 weeks on, 1 week off. During the 3-week 'on' period, take four 40mg tablets once daily with a low-fat breakfast, at the same time each day. During the 1-week 'off' period, do not take any regorafenib — this break helps the body recover.

Q: What should I do if I get severe tummy pain suddenly?

Seek emergency medical help immediately. Regorafenib carries a risk of bowel perforation — a hole forming in the intestinal wall — which is a life-threatening emergency. Sudden severe abdominal pain needs a same-day emergency assessment.

 

Customer Feedback


Recently Viewed